#TBT This week marked the 5-year anniversary of the fda's approval of CAR T cell therapy, the first-ever personalized cellular cancer treatment developed at Penn Medicine's Abramson Cancer Center. In 2017, CAR T cell therapy was only approved to treat a certain type of acute lymphoblastic leukemia (ALL). Now, there are now six FDA-approved CAR T cell therapies, for six different cancers, including pediatric and adult ALL and several other blood cancers. More than 15,000 patients across the world who’d run out of options have now received these transformative treatments. Dozens more clinical trials are in progress, including those for breast, ovarian and pancreatic cancer, plus other diseases including HIV/AIDS, diabetes, and lupus. Work in the lab is aimed at harnessing the approach for heart disease and dementia. Join us in celebrating this remarkable milestone as we continue our work in pursuit of a cure for all cancers. Link in bio for more. #cancermoonshot #cartcelltherapy #c...